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Background: Glioblastoma Multiforme (GBM) is the most common primary malignant tumor of the central nervous
system. Standard of care includes maximal resection followed by chemoradiotherapy. Tumors need adequate
perfusion and neovascularization to maintain oxygenation and for removal of wastes. Vascular endothelial growth
factor (VEGF) is a well characterized pro-angiogenic factor. We hypothesized that the increases in urinary VEGF levels
would occur early in the course of tumor recurrence or progression. We examine the feasibility of collecting and
analyzing urinary VEGF levels in a prospective, multi-institutional trial (Radiation Therapy Oncology Group, RTOG,
0611) as well as the role of VEGF as a marker of tumor recurrence.
Method: We evaluated VEGF levels in urine specimens collected post-operatively, at the conclusion of radiation
therapy (RT) and one month following RT. Urinary VEGF levels were correlated with tumor progression at one year.
VEGF levels were measured by enzyme-linked immunosorbant assay in urine specimens and normalized to urinary
creatinine levels. Sample size was determined based on a 50% 1-year recurrence rate. With a sensitivity and
specificity of 80%, the expected 95% confidence interval was (0.69, 0.91) with 100 patients. A failure was defined as
documented disease progression, recurrence or death before one year.
Results: 202 patients were enrolled between February-2006 and October-2007. Four patients were ineligible as they
did not receive RT. Of the remaining 198 patients, 128 had all three samples collected. In this group, 35 patients
(27.3%) did not progress, 89 (69.5%) had progression and 4 (3.1%) died without evidence of progression. Median
VEGF levels at baseline were 52.9 pg/mg Cr (range 0.2- 15,034.4); on the last day of RT, 56.6 (range 0–2,377.1); and
at one month follow-up, 70.0 (range 0.1-1813.2). In patients without progression at 1-year, both baseline VEGF level
and end of RT VEGF level were lower than those of patients who progressed: 40.3 (range 0.2-350.8) vs. 59.7
(range 1.3-15,034.4) and 41.8 (range 0–356.8) vs. 69.7 (range 0–2,377.1), respectively. This did not reach statistical
significance. Comparison of the change in VEGF levels between the end of RT and one month following RT,
demonstrated no significant difference in the proportions of progressors or non-progressors at 1-year for either
the VEGF increased or VEGF decreased groups.
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Conclusion: Urine can be collected and analyzed in a prospective, multi-institutional trial. In this study of patients
with GBM a change in urinary VEGF levels between the last day of RT and the one month following RT did not
predict for tumor progression by one year.
Keywords: VEGF (vascular endothelial factor), Glioblastoma Multiforme (GBM), Urinary biomarker, Radiation therapy,
Tumor recurrenceBackground
Glioblastoma Multiforme (GBM) is the most frequent pri-
mary malignant brain tumor in adults [1,2]. Its treatment
generally includes maximally safe surgical resection follo-
wed by adjuvant radiation therapy and temozolomide
chemotherapy [3]. Despite advances in understanding the
biology behind GBM [1,4,5] and some improvement in
outcome with the addition of temozolomide chemo-
therapy, its prognosis remains grim with a median overall
survival (OS) of 15 months [6].
Personalized therapy based on tumor biology in indi-
vidual patients to improve treatment outcome has iden-
tified several potential biomarkers [5,7,8], including
vascular endothelial growth factor (VEGF) [9]. Increased
VEGF activity has been associated with early recurrence
in patients with cancer including GBM [10-12]. VEGF
can be measured in biofluids such as urine, serum or
plasma [13-15]. The measurement of VEGF in urine is
an attractive option as urine collections are noninvasive,
there are minimal preparation costs and urinary proteins
are stable during long term storage [16,17]. In addition,
the measurement of VEGF in serum or plasma can be
problematic as VEGF can be released by platelets in the
process of phlebotomy in the case of serum [15] and
sequestration of VEGF within platelets may make accur-
ate VEGF measurement difficult in the case of plasma
[13,14]. VEGF as a urinary biomarker has previously
been shown to be a predictive marker for progression
free survival (PFS) in cancer patients after the comple-
tion of radiotherapy (RT) [10]. Its potential importance
to the treatment of GBM is based on its role in pro-
angiogenesis.
VEGF is responsible for increased vascularity and
vascular permeability in tumors as well as migration and
proliferation of endothelial cells [18,19]. VEGF mRNA
has been identified in pseudopalisading cells around
necrotic zones in GBM and its expression correlates
with grade in diffuse astrocytomas [20]. We hypothe-
sized that increased urinary VEGF levels would predict
for recurrence or progression in patients with GBM
patients. The purpose of this study was to examine the
feasibility of collecting and analyzing urine in a prospect-
ive, multi-institutional trial and the potential utility of
urinary VEGF as a predictive biomarker for progression.
In order to explore the dynamic nature of this potentialrelationship, VEGF was measured in the urine of GBM
patients prior to radiation therapy, at completion and at
1 month follow-up.
Materials and methods
Specimen and data collection
Under institutional review board approval, following
informed consult, voided urine samples were collected
from 202 subjects with a diagnosis of primary GBM
between February 2006 and October 2007 on RTOG
study 0611. This study was approved by the National
Cancer Institute Institutional Review Board. A patient
was considered eligible if he/she was enrolled on an
RTOG GBM study (RTOG 0513 or RTOG 0525). RTOG
0525 is a two arm study in which patients were random-
ized to receive either standard adjuvant temozolomide
therapy or dose dense adjuvant temozolomide [21].
RTOG 0513 is a phase I/II trial in which patients
received Motexafin Gadolinium in one of 3 dose levels
in phase I, followed by the Motexafin Gadolinium max-
imum tolerated dose in phase II in conjunction with
standard treatment [22]. Among 202 enrolled, 4 patients
were subsequently considered ineligible as they did not
receive radiation therapy. Of these 198 patients, ade-
quate specimen for analysis at all three time points was
available for 128 patients. The urine collection protocol
and the need for adequate specimens and analysis have
been previously described [16,17]. A minimum of 5 cc of
urine was collected from each patient at baseline, at the
completion of radiation therapy, and at the 1 month
follow-up evaluation.
Specimen processing and analysis
Urine samples were sent by overnight courier covered
with dry ice to a central laboratory for processing and
storage. They were measured using a commercial ELISA
(enzyme-linked immunosorbant assay) system for VEGF
(R&D systems) as per previously published material
[16,17]. Urine creatinine levels were measured using the
Bayer DCA 2000 following standard protocol [16,17].
Statistical analysis
Sample size was calculated to determine estimates of
sensitivity and specificity for 1 year recurrence. A 50%
1 year recurrence rate was calculated based on prognostic
Table 1 Demographic and clinicopathologic
characteristics of the patient population as compared to





not used in the
analysis (n = 997)
Age
<50 39 (30.5%) 232 (23.3%)
≥50 89 (69.5%) 765 (76.7%)
Chi-square p-value = 0.07
Gender
Female 72 (56.3%) 570 (57.2%)
Male 56 (43.8%) 427 (42.8%)
Chi-square p-value = 0.84
KPS
60-80 45 (35.2%) 383 (38.4%)
90-100 83 (64.8%) 614 (61.6%)
Chi –square p-value = 0.47
Surgery
Biopsy 3 (2.3%) 47 (4.7%)
Partial resection 44 (34.4%) 459 (46.0%)
Total resection 81 (63.3%) 491 (49.2%)
Chi-square p-value = 0.01
Neurologic
function
No symptoms 55 (43.0%) 309 (31.0%)
Minor symptoms 48 (37.5%) 468 (46.9%)
Moderate
symptoms
24 (18.8%) 215 (21.6%)
Severe symptoms 1 (0.8%) 5 (0.5%)
Chi-square p-value = 0.02
RPA class
III 30 (23.4%) 175 (17.6%)
IV 74 (57.8%) 602 (60.4%)
V 24 (18.8%) 220 (22.1%)
Chi-square p-value = 0.24
MGMT status
Methylated 31 (25.0%) 269 (27.0%)




27 (21.8%) 201 (20.2%)
Chi-square p-value = 0.86
Treatment arms
Not randomized 28 (21.9%) 264 (26.5%)
Arm 1 58 (45.3%) 353 (35.4%)
Arm 2 42 (32.8%) 380 (38.1%)
Chi-square p-value = 0.09
Q1 first quartile, Q3 third quartile. RPA recursive partitioning analysis.
Krauze et al. Biomarker Research 2013, 1:29 Page 3 of 7
http://www.biomarkerres.org/content/1/1/29class average of the RTOG Recursive Partitioning Analysis
of Gliomas (RPA) [23,24]. With a sensitivity and specificity
of 80% for progression, the expected 95% confidence
interval was (0.82, 0.98) based on 100 patients. We calcu-
lated that 200 patients were required to ensure that at
least 100 patients would have usable specimens based on
a previous 50% rate of unusable specimens.
The distribution of VEGF was described with mean,
standard deviation, median, minimum and maximum,
Q1 (first quartile) and Q3 (third quartile). For the pur-
poses of calculating PFS a patient was considered to
have failed treatment if there was documented disease
before 1 year or if the patient died without disease
before 1 year. Chi-square tests were used to test the dis-
tribution difference of pretreatment characteristics of
this study and RTOG 0525 patients that were not used
in this study, and failure status at 1 year by the change
in VEGF from the end of radiation therapy to 1 month
post radiation therapy. A Receiver Operating Character-
istic (ROC) curve was used to determine the best cut off
range for predicting recurrence at 1 year. Logistic regres-
sion was used to assess the relationship between patient
characteristics and recurrence at 1 year. All testing was
done at the overall significance level of 0.05. Statistical
Analysis System (SAS, Cary, NC) was used to perform
these analyses.
Results
Of 202 enrolled patients the demographic, clinical and
pathologic characteristics of the patient population were
compared to a control set of patients enrolled in RTOG
0525 that were not enrolled in the current study
(Table 1). Compared to this reference, the patients ana-
lyzed in the current study differ significantly in the
extent of surgical resection and neurologic functional
status [23]. Patients on the current study were more
likely to have had gross total resection (p = 0.01, χ2) and
better neurological function (p = 0.02, χ2) compared to
the RTOG 0525 reference population. The most preva-
lent RPA class in our cohort was class IV (57.8%).
Fifty-three percent of patients were unmethylated at the
O6-methylaguanine DNA methyltransferase (MGMT)
promoter and 25% were methylated.
At 1 year, 35 (27.3%) patients had not progressed, 89
(69.5%) had progressed, and 4 (3.1%) died without pro-
gression. For the entire group of 128 patients, at baseline
the median VEGF level was 52.9 pg/mgCr (range 0.2-
15,034.4); on the last day of RT 56.6 pg/mgCr (range 0 –
2,377.1); and at 1 month following RT 70.0 pg/mgCr
(range 0.1-1,813.2). In patients who had not progressed at
1 year, both their baseline VEGF levels of 40.3 pg/mgCr
(range 0.2-350.8) as well as their end of RT VEGF levels of
41.8 pg/mgCr (range 0–356.8) were lower than the levels
in patients who had progressed at one year, 59.7 pg/mgCr
Table 2 Normalized VEGF change from the end of RT to
1 month post RT distributed by failure status at 1 year
Not failed
(neither progression
nor death) (n = 35)
Failed (progression
or death) (n = 93)
Normalised VEGF
Increased 22 (62.9%) 47 (50.5%)
Decreased 13(37.1%) 46 (49.5%)
Chi-square test p = 0.21.
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respectively. However, the differences among these groups
did not reach statistical significance.
The normalized VEGF change from the end of RT to
the 1 month post-RT measurement was compared
between patients who progressed by 1-year vs. those that
did not progress (Table 2). Chi-square test revealed no
significantly higher rate of failure in patients with
elevated VEGF at 1 month radiation therapy (p = 0.21).
On univariate and multivariate logistic regression ana-
lysis no significant correlations were identified for any of
the variables examined (randomization arm on RTOG
0525, methylation status, RPA class, baseline normalized
VEGF, and VEGF change from end of radiation therapy to
1 month follow-up) (Table 3). The area under the Receiver
Operating Characteristic (ROC) curve (AUC) is 0.5401,
suggesting that VEGF is not a useful biomarker to predict
recurrence at 1 year (Figure 1).Discussion
VEGF has emerged as a significant drug target due to its
importance as a pro-angiogenic cytokine in gliomas [4].
VEGF signaling is thought to occur in response to hypoxia
and results in the formation of vessels whether de novo or
from preexisting vasculature [25]. Its role may be espe-
cially important in gliomas as they exhibit aberrant
vessels, hypoxia and endothelial proliferation. IncreasingTable 3 Univariate and multivariate logistic regression analys
progression/death status at 1 year
Variable
(Bolded value has unfavorable outcome)
Assigned treatment (Arm 2 vs. Arm1)
Methylation status (unmethylated vs. methylated)
RPA (IV vs. III)
RPA (V vs. III)
Baseline Normalized VEGF (continuous)
Normalized VEGF change from End of RT to 1 month post RT (continuous)
Ϯ Odds ratio: the OR of 1 indicates no difference, and > 1 indicates higher failure raVEGF activity correlates with an increase in vascular
proliferation and increasing tumor grade in gliomas [26].
A number of drugs aimed at neutralizing VEGF receptors
are currently being investigated [9], most notably bevaci-
zumab, a monoclonal antibody that binds and neutralizes
VEGF. Bevacizumab has been approved for use in non-
small cell lung cancer, metastatic renal cell carcinoma,
and based on the BRAIN [27] and the NCI 06-C-0064E
studies [28] it has also been approved for use in patients
with recurrent GBM. The two GBM trials showed a
reduction in steroid use, temporary improvement in
neurological function and, in the BRAIN study, a PFS of
9.2 months. In the newly diagnosed GBM setting, a phase
II trial [29] has shown a PFS benefit with no OS benefit
when Avastin is used in conjunction with RT and temo-
zolomide, although subset analysis showed that RPA
class IV/V may have an OS benefit as well. The
addition of Avastin to the standard regimen of radi-
ation and temozolomide is currently being investi-
gated in large randomized phase III trials (RTOG
0825, BO21990).
Previously, Chan et al. [10] showed that urinary VEGF
levels at the end of radiotherapy compared to the level
at least 1 month post treatment to be predictive of 1 year
PFS in a variety of tumor types, including GBM. Thus,
the present study focused on VEGF as a potential
biomarker for tumor recurrence in patients with GBM
receiving chemoradiation. Our results show that the
patient population in the current study is largely re-
presentative of the RTOG0525 population, suggesting
applicability to GBM patients in general. However, we
measured no significant difference with respect to changes
in VEGF in the patients who failed treatment and those
who did not. Furthermore, no significant correlation was
found on univariate/multivariate analysis for either base-
line VEGF or the change in VEGF level. However only
25% of patients were found to have methylated MGMT in
the current study as compared to historical rates on the
order of 45% [5] to 50% [30-32]. As methylated MGMTis of patient characteristics and urinary VEGF for
Univariate Multivariate
p-value OR Ϯ (95% CI) p-value ORϮ (95% CI)
0.76 0.87 (0.36, 2.13) 0.76 0.86 (0.32, 2.28)
0.25 1.72 (0.68, 4.34) 0.18 2.04 (0.73, 5.75)
0.62 1.26 (0.51, 3.14) 0.99 0.99 (0.31,3.12)
0.17 2.50 (0.67, 9.31) 0.73 1.30 (0.29, 5.90)
0.34 1.001(0.998,1.004) 0.45 1.001 (0.998,1.005)
0.50 1.000 (0.999,1.001) 0.31 0.999 (0.998,1.001)
te with increasing values.
Figure 1 Receiver Operating Curve (ROC) for urinary VEGF. Area
under receiver Operating curve Curve = 0.5401.
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an improved outcome in GBM [33-36], this may affect the
survival outcome as patients may be more likely to fail
treatment. Recent analysis of the RTOG0525 results does
not suggest that this is the case as their outcomes are
comparable to published literature [31]. Randomization to
either arm was not statistically different suggesting that
standard chemotherapy vs. dose dense chemotherapy is
likely not a confounding factor with respect to urinary
VEGF (Table 1).
Limitations of the study include the small number of
patients (128) for whom adequate samples were available
as well as potentially the timing of VEGF measurement
and the lack of long term follow-up of urinary VEGF
levels. Although previous data [10] showed a correlation
between urinary VEGF levels and PFS in a population of
cancer patients, there is the possibility that the correlation
with respect to GBM may exist but is simply not being de-
tected in the current study as result of the timing of VEGF
measurement. VEGF secretion in quantities large enough
to be predictive for recurrence may not occur until a sig-
nificant burden of disease is present, which is less likely at
the end of treatment or even at the 1 month follow-up
point. The possibility remains that VEGF levels could in
fact be predictive at a later date that is still before a defini-
tive radiographic diagnosis could be made. In such a sce-
nario, they could potentially help distinguish progression
from pseudoprogression.
Despite this lack of statistical significance, baseline
values for VEGF were higher for patients who progressedby 1 year. This was the case both at baseline as well
as at the end of radiotherapy. This may support the
idea that at the very least urinary VEGF may have
value as a prognostic if not necessarily as a predictive
biomarker in GBM.
Recent studies have revealed significant heterogeneity
within gliomas and even within the narrowly defined
GBM histology [1,37,38]. Based on the GBM subtypes
identified in Verhaak et al., it is possible that VEGF
levels may be predictive in some GBM subtypes spe-
cifically the mesenchymal or classical. EGFR activation
(classical subtype) and PTEN mutation (mesenchymal
subtype) have both been associated with increased VEGF
expression [4]. Further studies could examine a possible
correlation between VEGF levels and molecular GBM
subtypes and possibly include VEGF level within the risk
classification itself. A possible correlation between
GBM subtypes and VEGF was not addressed in the
current study. RTOG 0825, one of the two ongoing
phase III trials involving bevacizumab, includes pa-
tient stratification by mesenchymal/angiogenic gene
expression and may indirectly explore this potential
relationship.
Conclusion
Urinary VEGF was not identified as a predictive fac-
tor for tumor recurrence in GBM patients receiving
radiation therapy. There is a suggestion that baseline
and post treatment VEGF levels may be higher in
patients who ultimately fail treatment although this
was not statistically significant. This study confirmed
that urine can be collected and analyzed in a prospective,
multi-institutional trial.
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